Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy ; volume:30 ; number:1 ; day:20 ; month:1 ; year:2024 ; pages:1-16 ; date:12.2024
Molecular medicine ; 30, Heft 1 (20.1.2024), 1-16, 12.2024
- Urheber
-
Qin, Ge
Bai, Fan
Hu, Huabin
Zhang, Jianwei
Zhan, Weixiang
Wu, Zehua
Li, Jianxia
Fu, Yang
Deng, Yanhong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10020-024-00780-4
- URN
-
urn:nbn:de:101:1-2024033121252589832576
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Qin, Ge
- Bai, Fan
- Hu, Huabin
- Zhang, Jianwei
- Zhan, Weixiang
- Wu, Zehua
- Li, Jianxia
- Fu, Yang
- Deng, Yanhong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers